共 50 条
- [41] Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell CarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 663 - 670Milbury, KathrinSpelman, AmyWood, ChristopherMatin, Surena F.Tannir, NizarJonasch, EricPisters, LouisWei, QiCohen, Lorenzo
- [42] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatmentJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Drabkin, H. A.Figlin, R. A.Stadler, W. M.Hutson, T. E.Hajdenberg, J.Chu, L.Trent, D.Campos, L. T.Kelly, F.Bukowski, R. M.
- [43] Advanced renal cell carcinomaCurrent Treatment Options in Oncology, 2001, 2 (5) : 437 - 445Milowsky M.I.Nanus D.M.
- [44] Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Escudier, B. J.Negrier, S.Gravis, G.Chevreau, C.Delva, R.Bay, J.Geoffrois, L.Lagouffe, E.Blanc, E.Ferlay, C.
- [45] A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)Voss, Martin HennerChen, YingbeiChaim, JoshuaCoskey, Devyn TaylorWoo, KaitlinPatil, SujataMolina, Ana M.Hsieh, JamesMotzer, Robert J.Feldman, Darren Richard
- [46] Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugsJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)Lee, Chung-HanHoetker, Andreas M.Voss, Martin HennerFeldman, Darren RichardWoo, KaitlinPatil, SujataCoskey, Devyn TaylorAkin, OguzHsieh, JamesMotzer, Robert J.
- [47] Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Cella, DavidGranwald, ViktorEscudier, BernardHammers, Hans J.George, SabyNathan, PaulGrimm, Marc-OliverRini, Brian I.Doan, JustinIvanescu, CristinaPaty, JeanMekan, SabeenMotzer, Robert J.
- [48] Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (03) : 312 - 323Vasudev, Naveen S.Ainsworth, GemmaBrown, SarahPickering, LisaWaddell, TomFife, KateGriffiths, RichardSharma, AnandKatona, EszterHoward, HelenVelikova, GalinaMaraveyas, AnthonyBrown, JanetPezaro, CarmelTuthill, MarkBoleti, EkateriniBahl, AmitSzabados, BernadettBanks, Rosamonde E.Brown, JoanneVenugopal, BalajiPatel, PoulamJain, AnkitSymeonides, Stefan N.Nathan, PaulCollinson, Fiona J.Powles, Thomas
- [50] Phase I Trial of Bevacizumab followed by Concurrent Radiation, Bevacizumab and Cisplatin for Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S104 - S104Harari, P. M.Khuntia, D.Traynor, A. M.Hoang, T.Hartig, G. K.McCulloch, T. M.Jeraj, R.Nyflot, M.Wiederholt, P. A.Gentry, L. R.